Global mycoplasma testing market size is expected to reach US$ 1,907.6 Mn by 2031, from US$ 997.8 Mn in 2024, exhibiting a compound annual growth rate (CAGR) of 9.7% during the forecast period.
Mycoplasma testing is essential in the field of biotechnology and pharmaceuticals. There are different types of products available in the market for mycoplasma testing. The major products can be categorized into two types - kits and services.
Global Mycoplasma Testing Market- Regional Insights
- North America is expected to be the largest market for mycoplasma testing during the forecast period, accounting for over 35.7% of the market share in 2024. North America has established itself as the dominant regional market for mycoplasma testing. The region is home to several leading life sciences companies that are pioneering innovation in sequencing technology. Strong government funding for biomedical research has encouraged rapid technological advancements in the field.
- Asia Pacific is expected to be the second-largest market for mycoplasma testing market, accounting for over 25.2% of the market share in 2024. Asia Pacific is the fastest growing regional market for mycoplasma testing. Several factors contribute to the region's burgeoning growth rate. Countries like China and India are making vast public investments to build out their genomics capabilities as part of ambitious national bioscience development agendas.
- The mycoplasma testing market in Europe is experiencing robust growth, driven by advancements in research and developments (R&D) and increasing inorganic strategies by the market players is expected to aid in the market growth over the forecast period.
Figure 1. Global Mycoplasma Testing Market Share (%), By Region, 2024
To learn more about this report, request a free sample copy
Analyst’s Views: Global mycoplasma testing market is experiencing steady growth driven by factors such as increasing R&D investments by the market players, increasing funding by the government moreover market players are focusing on inorganic strategies such as merger and acquisition which is expected to aid in the market growth over the forecast period.
Global Mycoplasma Testing Market- Drivers
- Rising research and development activities by the market players: Increasing research and development activities by the market players is expected to drive the market growth over the forecast period. For instance, in April 2022, AlphaBiolabs, a biotechnology company launched STI testing for members of the public and healthcare partners. The complete panel (7 STIs) detects chlamydia, gonorrhea, mycoplasma genitalium, mycoplasma hominis, trichomoniasis, and ureaplasma parvum (UTI), and urea urealyticum (UTI) bacterias.
- Increasing research and development (R&D) expenditure: Increasing investment in research and development by biopharmaceutical companies is a major factor driving the growth of the global mycoplasma testing market. With more focus on developing novel drug therapies to treat various chronic and life-threatening diseases, biopharma players are under pressure to launch new products in the market within stringent regulatory timelines.
Global Mycoplasma Testing Market- Opportunities
- Emerging economies in Asia Pacific, Middle East, and Africa regions: The emerging economies in Asia Pacific, Middle East, and Africa regions offer immense growth opportunities for the global mycoplasma testing market. These regions are witnessing rapid economic development backed by a steadily growing population, rising disposable incomes and strong investments in healthcare infrastructure
Global Mycoplasma Testing Market Report Coverage
| Report Coverage |
Details |
|---|
| Base Year: |
2023 |
Market Size in 2024: |
US$ 997.8 Mn |
|---|
| Historical Data for: |
2019 to 2023 |
Forecast Period: |
2024 - 2031 |
|---|
| Forecast Period 2024 to 2031 CAGR: |
9.7% |
2031 Value Projection: |
US$ 1,907.6 Mn |
|---|
| Geographies covered: |
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
|
| Segments covered: |
- By Product Type: Kits & Reagents, Instruments
- By Application: Cell Line Testing, Virus Testing, End of Production Testing, Others (Raw Material Testing, etc.)
- By End User: Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes
|
| Companies covered: |
Charles River Laboratories International, Merck KGaA, Lonza Group Ltd, Roche Diagnostics, Thermo Fisher Scientific, Merck, InvivoGen, Creative Bioarray, and Other Prominent Players
|
| Growth Drivers: |
- Rising research and development activities by the market players
- Increasing R&D Expenditure
|
| Restraints & Challenges: |
|
Global Mycoplasma Testing Market- Trends
- Increasing product launched by the market players: Increasing product launches by the market players is expected to drive the market growth over the forecast period. For instance, in July 2020, bioMérieux, a multinational biotechnology company launched BIOFIRE MYCOPLASMA, an innovative test for mycoplasma detection in the U.S. for pharmaceutical products
Global Mycoplasma Testing Market - Restraints
- High equipment costs: The high cost of instruments that is required for mycoplasma testing is a significant barrier impacting the expansion of the global mycoplasma testing market. Conducting mycoplasma testing involves procuring expensive equipment such as PCR systems, ELISA readers, microbial culture supplies, and others. These instruments have substantial initial purchase prices, ranging from tens of thousands to several hundred thousand dollars depending on the technique. Moreover, their annual maintenance and calibration costs are also steep. This heavy capital expenditure poses serious budgeting challenges for small and medium size laboratories and research facilities, especially in cost-sensitive developing markets. The high capital requirement limits their affordability and accessibility to perform mycoplasma testing on a regular basis as mandated by regulatory guidelines.
Counterbalance: To counter balance this restraint, market players need to reconsider all other viable factors before mentioning the cost of the equipment, thereby making the mycoplasma testing costs affordable.
Figure 2. Global Mycoplasma Testing Market Share (%), By Product Type, 2024
To learn more about this report, request a free sample copy
Global Mycoplasma Testing Market- Recent Developments
Key Developments
- On January 23, 2019, Reading Scientific Services (RSSL), a pharmaceutical research company, introduced the U.K.’s first same-day mycoplasma testing service for manufacturers of biologic medicines.
Business Development Activities by the Market Players
- On December 16, 2021, Asahi Kasei Medical Co., Ltd., a medical device and medical material company, announced an acquisition of Bionique Testing Laboratories LLC (Bionique), a company which offers in mycoplasma testing services for the biotherapeutics and life-sciences industries.
Top Companies in the Global Mycoplasma Testing Market
- Charles River Laboratories International
- Merck KGaA
- Lonza Group Ltd
- Roche Diagnostics
- Thermo Fisher Scientific
- Merck
- InvivoGen
- Creative Bioarray
- Other Prominent Players
Definition: Mycoplasma testing is essential in the field of biotechnology and pharmaceuticals. There are different types of products available in the market for mycoplasma testing. The major products can be categorized into two types - kits and services.
U.S.: 
U.K. : 
India :